{"classes":[{"categories":[{"measurements":[{"comment":"The upper 95% confidence interval was not reached due to Insufficient number of participants with events to reach the threshold according to Kaplan-Meier methodology.","groupId":"OG000","lowerLimit":"15.21","upperLimit":"NA","value":"26.18"},{"groupId":"OG001","lowerLimit":"9.26","upperLimit":"25.72","value":"16.59"},{"groupId":"OG002","lowerLimit":"11.63","upperLimit":"30.85","value":"18.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"75"}],"units":"Participants"}],"description":"DOR is the time from first response (complete remission (CR) or partial remission (PR)) to the date of initial objectively documented progression as determined using the 2007 IWG criteria or death due to any cause, whichever occurred first. For participants who neither progressed nor died, the DOR was censored on the date of their last tumor assessment. Participants who started subsequent therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy.\n\nCR is the percent of participants with a best overall response (BOR) of CR (disappearance of all evidence of disease) according to the 2007 IWG criteria, based on IRRC assessment.\n\nPR is the percent of participants with a best overall response (BOR) of PR (regression of measurable disease and no new sites) according to the 2007 IWG criteria, based on IRRC assessment.\n\nComputed using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG000","title":"Cohort A: Post-Transplant, Never Taken Brentuximab Vedotin"},{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG001","title":"Cohort B: Post Transplant, Brentuximab Vedotin Taken Post-Autologous Stem Cell Transplant"},{"description":"Nivolumab was administered at 3 mg/kg IV over 60 minutes on the first day of each 2-week cycle. Upon the implementation of revised protocol version 04c (dated 22-Aug-2019), participants were switched from a body weight-based dose of 3 mg/kg every 2 weeks to a flat dose of 480 mg every 4 weeks or a flat dose of 240 mg every 2 weeks. Nivolumab treatment was continued until unacceptable toxicity or disease progression.","id":"OG002","title":"Cohort C: Post Transplant, Brentuximab Vedotin Taken Pre-and/or Post-Autologous Stem Cell Transplant"}],"paramType":"MEDIAN","populationDescription":"All treated Cohort A, B and C participants with objective response of CR or PR.","reportingStatus":"POSTED","timeFrame":"From first dose to the date of initial objectively documented progression or the date of subsequent therapy, or death whichever occurred first (up to approximately 100 months).","title":"Duration of Objective Response Based on IRRC Assessments in Cohorts A, B, and C","type":"SECONDARY","unitOfMeasure":"Months"}